Status:
SUSPENDED
The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19
Lead Sponsor:
Larry Saltzman, MD
Conditions:
Covid-19
Eligibility:
All Genders
Brief Summary
Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations auth...
Detailed Description
LLS has partnered with Adaptive Biotechnologies, to provide their ImmunoSEQ research assay to accumulate data about patients with blood cancer, who have received an FDA authorized vaccination, and dep...
Eligibility Criteria
Inclusion
- Select patients participating in the LLS COVID-19 Registry will be invited to enroll
Exclusion
- People who have not participated in the LLS COVID-19 Registry
Key Trial Info
Start Date :
May 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 20 2031
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04898985
Start Date
May 20 2021
End Date
May 20 2031
Last Update
August 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lymphoma and Leukemia Society
Rye Brook, New York, United States, 10573